Fresenius Medical Care (NYSE:FMS - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of $0.45 per share and revenue of $4.71 billion for the quarter.
Fresenius Medical Care Price Performance
FMS stock traded up $0.60 during mid-day trading on Friday, hitting $25.62. 1,147,884 shares of the stock were exchanged, compared to its average volume of 319,679. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The stock has a market capitalization of $15.03 billion, a price-to-earnings ratio of 21.17, a PEG ratio of 0.76 and a beta of 0.85. The business has a fifty day moving average price of $24.15 and a 200 day moving average price of $23.20. Fresenius Medical Care has a 12 month low of $17.93 and a 12 month high of $26.04.
Wall Street Analysts Forecast Growth
Several research firms recently commented on FMS. Truist Financial lifted their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a "hold" rating in a research report on Monday, January 6th. StockNews.com upgraded shares of Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th.
Read Our Latest Analysis on Fresenius Medical Care
Fresenius Medical Care Company Profile
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
See Also
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
